Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rosiglitazone.

J A Balfour1, G L Plosker

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 10, 1999
PubMed
Summary

Rosiglitazone, an antidiabetic drug, effectively lowers blood glucose and HbA1c in type 2 diabetes patients. It improves insulin resistance and shows a low risk of hypoglycemia, unlike other agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Colesevelam.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2004
Same author

Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis.

American journal of clinical dermatology·2002
Same author

Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.

PharmacoEconomics·2002

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus is characterized by insulin resistance.
  • Thiazolidinedione agents are used to treat this condition.
  • Rosiglitazone is a thiazolidinedione with potential benefits.

Purpose of the Study:

  • To evaluate the efficacy and safety of rosiglitazone in type 2 diabetes.
  • To assess its impact on glycemic control and insulin sensitivity.
  • To compare its safety profile with other antidiabetic agents.

Main Methods:

  • Animal models of insulin resistance were used to assess effects on glucose, insulin, triglycerides, and diabetic complications.
  • Clinical trials evaluated rosiglitazone monotherapy and combination therapy (with sulfonylurea, metformin, or insulin) in type 2 diabetes patients.
  • Measurements included fasting plasma glucose, glycosylated hemoglobin (HbA1c), insulin sensitivity, and beta-cell function using homeostasis model assessment.

Main Results:

  • Rosiglitazone decreased plasma glucose, insulin, and triglyceride levels in animal models.
  • In clinical trials, rosiglitazone improved glycemic control, reducing fasting plasma glucose and HbA1c.
  • Combination therapy with rosiglitazone further enhanced glycemic control and improved insulin sensitivity and beta-cell function.
  • Rosiglitazone demonstrated a low risk of hypoglycemia (<2% in monotherapy) and no significant drug interactions.
  • Unlike troglitazone, rosiglitazone did not induce cytochrome P4503A4 metabolism and showed no evidence of hepatotoxicity.

Conclusions:

  • Rosiglitazone is an effective agent for improving glycemic control and insulin resistance in type 2 diabetes mellitus.
  • It offers a favorable safety profile with a low risk of hypoglycemia and no significant drug interactions.
  • Rosiglitazone represents a valuable therapeutic option for managing type 2 diabetes, potentially without the hepatotoxicity concerns associated with troglitazone.

Related Experiment Videos